Breaking news

Unlocking Potential: Eurobank And National Bank Of Greece Ratings Update

In an insightful update by Morningstar DBRS, Eurobank S.A. has been given a nod towards future growth with a shift in its outlook to positive. Meanwhile, the National Bank of Greece holds steady with a stable outlook. These changes come amidst evolving financial strategies and market dynamics.

Eurobank’s Positive Trajectory

Eurobank’s recent rating boost results from its enhanced capability to secure profitability and asset quality, post its strategic acquisition of Hellenic Bank in Cyprus. Anticipated moderate profitability, bolstered by loan growth and revenue diversification, offsets the challenges of lower interest rates and rising operational costs.

National Bank Of Greece’s Steady Path

Despite facing potential declines in profitability due to economic factors, the National Bank of Greece remains fortified. Its robust capital reserves and asset quality improvements provide a solid foundation against external economic pressures. The bank’s ongoing strategies in issuing new loans and optimizing costs indicate resilience.

Conclusion

The evolving financial strategies of Eurobank and the National Bank of Greece signify a transformative period for these institutions as they navigate complex economic landscapes. Stakeholders worldwide watch closely as these banks aim to maintain a robust economic stance amidst global market shifts.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

eCredo
Uol
Aretilaw firm
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter